Lopinavir (ABT-378): Potent HIV Protease Inhibitor for Antiviral Research

Executive Summary: Lopinavir is a potent, selective inhibitor of HIV protease, displaying K_i values of 1.3–3.6 pM against both wild-type and mutant forms, with an EC₅₀ below 0.06 μM in resistant strains (APExBIO). Its activity is retained in human serum, showing approximately 10-fold greater potency than ritonavir in this context. Oral administration in animal models yields a C_max of 0.8 μg/mL at 10 mg/kg and 25% bioavailability, with plasma levels declining by 6 hours post-dose. Co-administration with ritonavir increases systemic exposure 14-fold. Lopinavir also demonstrates cross-pathogen activity, inhibiting MERS-CoV replication in vitro at low micromolar concentrations (de Wilde et al. 2014).

Biological Rationale

HIV-1 protease is an essential aspartyl protease involved in the maturation of infectious HIV particles. Protease inhibitors (PIs) disrupt viral replication by preventing the cleavage of the Gag-Pol polyprotein, leading to non-infectious viral progeny (see related article). Lopinavir, a ritonavir analog with optimized side-chain modifications, was developed to overcome resistance mutations, notably at the Val82 site, and to maintain efficacy in the presence of serum proteins. This design addresses key challenges in antiretroviral therapy development: resistance, pharmacokinetic variability, and protein binding (APExBIO).

Mechanism of Action of Lopinavir

Lopinavir binds reversibly to the active site of HIV-1 protease, preventing substrate cleavage. Its structure incorporates side-chain alterations that reduce steric clash at the Val82 residue, which is frequently mutated in resistant HIV strains. This enables Lopinavir to inhibit both wild-type and mutant proteases effectively at picomolar concentrations. In the context of serum proteins, Lopinavir retains high free drug levels, unlike ritonavir, due to lower serum protein binding, thus preserving antiviral activity in vivo. Additionally, Lopinavir demonstrates a favorable pharmacokinetic profile when co-administered with ritonavir, which inhibits CYP3A-mediated metabolism, significantly increasing Lopinavir's systemic exposure (extended discussion).

Evidence & Benchmarks

• Lopinavir exhibits a K_i of 1.3–3.6 pM against wild-type and mutant HIV-1 protease (APExBIO, product data).
• EC₅₀ against Val82 mutant HIV protease is <0.06 μM in cell-based assays (APExBIO, product data).
• Shows approximately 10-fold higher potency than ritonavir in the presence of 50% human serum (APExBIO).
• Active in vitro against MERS-CoV with EC₅₀ values in the 3–8 μM range (de Wilde et al. 2014).
• In animal models, oral dosing at 10 mg/kg yields a C_max of 0.8 μg/mL and 25% bioavailability, with plasma levels undetectable after 6 hours (APExBIO).
• Co-administration with ritonavir increases Lopinavir AUC by 14-fold (APExBIO, product data).
• Effective at 4–52 nM in cell-based HIV protease inhibition assays (see benchmarking overview).

Applications, Limits & Misconceptions

Lopinavir is widely used in HIV protease inhibition assays, HIV drug resistance studies, and antiretroviral therapy development. Its robust activity in the presence of serum and against resistant strains makes it suitable for quantitative, clinically relevant workflows. Lopinavir also serves as a research tool in cross-pathogen antiviral studies, including coronavirus models (de Wilde et al. 2014).

• This article extends prior discussions by providing updated pharmacokinetic benchmarks and clarifying protocol details for serum-containing assays.
• This overview adds quantitative benchmarks and cross-pathogen evidence not covered in previous summaries.

Common Pitfalls or Misconceptions

• Lopinavir is not water-soluble; stock solutions must be prepared in DMSO or ethanol at ≥31.45 mg/mL or ≥48.3 mg/mL, respectively (APExBIO).
• It is not effective as monotherapy in vivo due to rapid metabolism; co-administration with ritonavir is required for optimal systemic exposure.
• Lopinavir does not cure HIV infection; it suppresses viral replication as part of combination antiretroviral therapy.
• In coronavirus models, Lopinavir inhibits viral replication in vitro but is not an approved or proven therapy for coronaviral infections in humans (de Wilde et al. 2014).
• Stability is compromised at room temperature; solutions should be stored at –20°C and prepared fresh.

Workflow Integration & Parameters

Lopinavir (SKU A8204) from APExBIO is supplied as a solid, with a molecular weight of 628.81 g/mol and chemical formula C₃₇H₄₈N₄O₅. For in vitro assays, dissolve in DMSO or ethanol to desired concentrations. It is effective at 4–52 nM in cell-based HIV protease inhibition assays. In resistance profiling, include both wild-type and mutant proteases. For in vivo studies, oral administration at 10 mg/kg achieves representative plasma levels; combine with ritonavir for enhanced exposure. Store all solutions at –20°C and use within recommended time frames to preserve potency (APExBIO).

Conclusion & Outlook

Lopinavir (ABT-378) remains a benchmark compound for HIV protease inhibition and antiviral research. Its serum resilience, resistance management, and favorable pharmacokinetics—especially when paired with ritonavir—make it indispensable for HIV infection research and drug development. Ongoing studies continue to evaluate Lopinavir's cross-pathogen potential. For validated protocols and product support, refer to the APExBIO Lopinavir A8204 kit.